These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 37845557

  • 1. Immune Checkpoint Inhibitor-Induced (Type 3) Autoimmune Pancreatitis.
    Shirwaikar Thomas A, Chari ST.
    Curr Gastroenterol Rep; 2023 Oct; 25(10):255-259. PubMed ID: 37845557
    [Abstract] [Full Text] [Related]

  • 2. Type 3 autoimmune pancreatitis (immune checkpoint inhibitor-induced pancreatitis).
    Sayed Ahmed A, Abreo M, Thomas A, Chari ST.
    Curr Opin Gastroenterol; 2022 Sep 01; 38(5):516-520. PubMed ID: 35881977
    [Abstract] [Full Text] [Related]

  • 3. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury.
    Abu-Sbeih H, Tang T, Lu Y, Thirumurthi S, Altan M, Jazaeri AA, Dadu R, Coronel E, Wang Y.
    J Immunother Cancer; 2019 Feb 06; 7(1):31. PubMed ID: 30728076
    [Abstract] [Full Text] [Related]

  • 4. Pancreatic involvement due to immune checkpoint inhibitors: a proposed classification.
    Ashkar M, Chandra S, Vege SS, Takahashi H, Takahashi N, McWilliams RR.
    Cancer Immunol Immunother; 2023 Apr 06; 72(4):895-901. PubMed ID: 36161510
    [Abstract] [Full Text] [Related]

  • 5. Immune Checkpoint Inhibitor-related Pancreatitis: A Case Series, Review of the Literature and an Expert Opinion.
    Kramer S, van Hee K, Blokzijl H, van der Heide F, Visschedijk MC.
    J Immunother; 2023 Sep 01; 46(7):271-275. PubMed ID: 37216403
    [Abstract] [Full Text] [Related]

  • 6. Autoimmune Pancreatitis Type 2: Diagnostic Utility of PD-L1 Immunohistochemistry.
    Gupta R, Neyaz A, Chougule A, Akita M, Zen Y, Forcione D, Castillo CF, Ferrone CR, Deshpande V.
    Am J Surg Pathol; 2019 Jul 01; 43(7):898-906. PubMed ID: 31135488
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pancreatic adverse events in patients treated with immune checkpoint inhibitors.
    Hana C, Rehman T, Park K, Carracedo Uribe C, Aung PP, Hunis B, Salzberg M, Zikria J, Hussein A.
    JGH Open; 2023 Mar 01; 7(3):204-207. PubMed ID: 36968572
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Immune-related adverse events in various organs caused by immune checkpoint inhibitors.
    Okiyama N, Tanaka R.
    Allergol Int; 2022 Apr 01; 71(2):169-178. PubMed ID: 35101349
    [Abstract] [Full Text] [Related]

  • 12. Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis.
    Zhao Z, Zhang W, Pang L, Zeng L, Liu S, Liu J.
    Front Immunol; 2023 Apr 01; 14():1166299. PubMed ID: 37359551
    [Abstract] [Full Text] [Related]

  • 13. [A young woman with auto-immune pancreatitis].
    Zoutendijk R, van Santvoort HC, Raicu MG, Bollen TL, Verdonk RC.
    Ned Tijdschr Geneeskd; 2023 Mar 16; 167():. PubMed ID: 36928874
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Insulin secretion improvement during steroid therapy for autoimmune pancreatitis according to the onset of diabetes mellitus.
    Noguchi K, Nakai Y, Mizuno S, Isayama H, Hirano K, Kanai S, Nakamura T, Uchino R, Takahara N, Kogure H, Tada M, Koike K.
    J Gastroenterol; 2020 Feb 16; 55(2):198-204. PubMed ID: 31471733
    [Abstract] [Full Text] [Related]

  • 16. Pancreatic injury in patients treated with immune checkpoint inhibitors: a retrospective multicenterstudy.
    Nagao K, Sakai A, Tsumura H, Iemoto T, Hirata Y, Hori H, Ogisu K, Kakuyama S, Ikegawa T, Hirata T, Ezaki T, Furumatsu K, Yamanaka K, Kato T, Fujigaki S, Tanaka H, Yagi Y, Tanaka T, Kobayashi T, Masuda A, Shiomi H, Kodama Y.
    J Gastroenterol; 2024 May 16; 59(5):424-433. PubMed ID: 38421473
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
    Grimmelmann I, Momma M, Zimmer L, Hassel JC, Heinzerling L, Pföhler C, Loquai C, Ruini C, Utikal J, Thoms KM, Kähler KC, Eigentler T, Herbst RA, Meier F, Debus D, Berking C, Kochanek C, Ugurel S, Gutzmer R, German Dermatooncology Group (DeCOG).
    Eur J Cancer; 2021 May 16; 149():1-10. PubMed ID: 33812141
    [Abstract] [Full Text] [Related]

  • 19. Pancreatitis and Hyperlipasemia in the Setting of Immune Checkpoint Inhibitor Therapy.
    Townsend MJ, Liu M, Giobbie-Hurder A, Sack JS, LeBoeuf NR, Hodi FS, McNabb-Baltar J, Grover S.
    J Natl Compr Canc Netw; 2023 Aug 16; 21(8):831-840.e3. PubMed ID: 37549912
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.